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Mutations in the tetratricopeptide repeat domain 7A (TTC7A) gene cause a severe form of 
very early-onset inflammatory bowel disease (VEOIBD)1. TTC7A has a crucial role in 
chaperoning the enzyme phosphatidylinositol-4-Kinase-3-alpha from the Trans-Golgi 
apparatus to the plasma membrane to facilitate phosphorylation of phosphatidylinositol (PI). 
The composition of the plasma membrane in particular levels of phosphorylated PI (PI-4P) 
are crucial for preserving epithelial cell polarity and survival1-3. The clinical spectrum of the 
disease varies from multiple intestinal atresias (MIA) to severe autoimmune enterocolitis 
clinically evident by infantile-onset intestinal obstruction/failure, bleeding and diarrhoea1,4-6. 
Furthermore, the disease can be associated with severe immunodeficiency or autoimmune 
phenomena owing to the central role of TTC7A in thymic architecture7. Limited published 
data on TTC7A deficient patients suggests a median survival <12 months of age1,4-9. 
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a possible treatment 
option for therapy-refractory VEOIBD with or without genetic diagnosis, especially when 
associated with immunological impairment10-13. Moreover, evidence on the interaction 
between haematopoietic donor and host epithelial cells in stem cell transplantation might 
lead to potential benefit of HSCT in certain epithelial disorder14-16. TTC7A deficient patients 
with associated immunodeficiency may therefore benefit from HSCT, however the effect of 
engrafted donor cells on chronic intestinal inflammation and gut epithelial tissue regeneration 
is unknown14-15. Follow-up data on HSCT in TTC7A-deficiency is required to understand the 
impact of this treatment on the disease phenotype and to guide the management of future 
cases. In this study, we report the clinical and histological evolution of four TTC7A-deficient 
patients who are alive 19 to 114 months post HSCT.  
Anthropometric data, clinical features and laboratory results from affected patients were 
extracted from clinical notes and prospective databases. One of the four patients included in 
this study was previously reported with shorter post-HSCT follow up6. We recruited 
candidates for molecular evaluation, including NGS, as part of the PETIT Study (Patients 
with Early-onseT Intestinal inflammaTion Study). The molecular diagnosis was established 
through whole exome sequencing in three patients (in one case as previously reported6, for 
the other two Beckman Coulter Genomics on Illumina HiSeq2000, SureSelect Human All 
Exon Kit Version 4 Agilent Technologies; Alignment: Burrows-Wheeler Aligner software; 
Refinement: Genome Analysis Tool Kit) and targeted sequencing in one patient (PCR 
according to standardised diagnostic laboratory criteria, protocol on request). Intestinal 
biopsies were fixed, paraffin embedded and stained (haematoxylin and eosin) according to 
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standardised diagnostic laboratory criteria (protocol on request). Patients were informed and 
consented for functional studies and genetic sequencing as part of the PETIT Study. Ethical 
approval was obtained from the National Research Ethics Service Committee London, 
Bloomsbury. Between 2005 and 2013, three patients with TTC7A deficiency were treated at 
Great Ormond Street Hospital, London, UK and one at Boston Children’s Hospital in Boston, 
MA, USA (extended medical histories in supplemental material). In one case, a family history 
of early infantile deaths due to obstructive intestinal disease in the patients’ siblings was 
established. All children were diagnosed antenatally with bowel obstruction, required multiple 
surgeries in the neonatal period to address gut strictures and were parenteral nutrition (PN) 
dependent within the first six months of life. In three patients attempts to control intestinal 
inflammation by deploying multiple immunosuppressant agents were undertaken without 
consistent improvement. There was evidence of immune dysfunction/dysregulation in all 
patients varying from severe T- and NK-cell deficiency with impaired mitogen response and 
low T-cell receptor excision circles (TRECs) to mild TRECs impairment (Table 1, detailed in 
Table S3,S4). Patients received HSCT after reduced toxicity conditioning or serotherapy 
alone at 3, 9, 14 and 17 months of life (Table 1). At the time of writing, all children were alive 
at 19, 50, 66 and 114 months post-HSCT. Donor engraftment was complete in one and 
mixed in three patients with normal immune reconstitution in all children (Table 1, detailed in 
Table S3). Three patients required major surgical revisions for on-going gut strictures post-
HSCT, and two are still on immunosuppression. None of the patients could be weaned off 
PN, and two are currently listed for multivisceral transplantation due to additional liver 
dysfunction. Intestinal inflammation and abnormal epithelial features persisted beyond HSCT 
in all children (supplemental material, table S1) consistent with ongoing primary disease as 
opposed to a possible allogeneic phenomenon (i.e. gut graft versus host disease). Post 
HSCT, one patient developed severe sensorineural deafness and immune mediated 
hypothyroidism, one developed “flaky skin” phenotype and lung dysfunction of unclear origin. 
In three children, advanced liver disease with bridging fibrosis possibly due to long-term PN 
was established.  
Published data on TTC7A deficiency is scarce. Overall 52 cases with genetically confirmed 
TTC7A deficiency were reported in the literature 3, 6-9,15-16. Clinical outcomes are available for 
45 patients, 30 of whom have died (median age at death eight months). Fifteen reported pts 
are alive at a median age of 27 months. All of them have a severe gastro-intestinal disease 
(severe diarrhoea, gut failure, MIA), 6 are PN dependent, 11 show signs of 
immunodeficiency and/or autoimmune disorders1,6-8. Most of the reported patients were 
treated symptomatically and managed with supportive medical and surgical care. One 
reported case was referred for combined small intestine and HSCT but was lost to follow-up 
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6. Six published patients underwent HSCT of whom five died within the first year post 
procedure (3 from infections, 1 from disease progression, 1 from unknown causes)6,8,9,15. 
The only survivor is reported here as P4.  
Over 20 private mutations in the TTC7A gene have been described ranging from 
homozygous deletions as demonstrated in the first publication associating the TTC7A gene 
with MIA4 to compound heterozygous missense mutations1,6,8,9. There is insufficient 
evidence to suggest a correlation between type or position of the mutation within the TTC7A 
gene and clinical severity. This is confirmed by our findings. Survival, clinical and histological 
evolution of the disease appeared to be similar in our patients despite markedly different 
genotypes. P2 harboured a large homozygous deletion in exon 1 (Table 1, Figure 1) leading 
to a premature stop codon at the start of exon two (amino acid position 67) rendering the 
presence of a functional TTC7A protein highly unlikely. Considering that 3 patients in our 
cohort underwent HSCT at a higher median age than the reported median age of death in 
the literature, we suggest that disease severity plays a central role in early patient survival 
and eligibility to HSCT. All our patients are alive post HSCT, suggesting that reduced or 
minimal toxicity conditioning is a critical point to avoid transplantation-related mortality and 
still obtain T-cell engraftment. Our findings suggest that while HSCT was feasible and safe, 
correcting the immune dysfunction through HSCT in TT7A patients did not influence the 
epithelial phenotype nor promoted enteral tolerance. Restoring immunocompetence in 
patients with concomitant immunodeficiency may nevertheless increase the chance for long-
term survival limiting infection-related comorbidities across multiple surgeries and long-term 
PN. The role of HSCT in preventing immune mediated phenomena which appear later in life 
of TTC7A deficient patients has yet to be established, and is therefore difficult to include in 
the decision-making process7. Small bowel transplantation in genetically confirmed TTC7A 
deficiency has not yet been reported but given the overall improving results of intestinal 
transplantation in children, this might be an option in selected cases17,18. 
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Patient Genotype Immunology Gut Phenotype IS pre HSCT Donor 
Stem-Cell 
Source 
Conditioning  
Regimen 
GvHD Chimerism 
P1 
p.Glu191fs 
p.I854Phe 
 
 
Low IgG levels 
Impaired mitogen 
stimulation 
 
Pyloric stenosis 
Microcolon 
Autoimmune 
enterocolitis (PE) 
 
Steroids 
Azathioprine 
Infliximab 
Daclizumab 
 
Unrelated 
HLA 8/10 
 
CB 
 
TBI 2 Gy 
Cyclophosphamide 50 mg/kg 
Fludarabine 200 mg/m2 
ATG 7.5 mg/kg 
 
None 
 
CD3 = 51% donor 
CD15 = 15% donor 
P2 
p.Gly45_Ala55del 
p.Gly45_Ala55del 
 
 
Low IgG levels 
Reduced TRECs 
 
D/AC/TC Atresias 
Microcolon 
Autoimmune 
enterocolitis (PE) 
 
Steroids 
Infliximab 
Basiliximab 
Cyclosporine 
 
 
Sibling 
HLA 10/10 
 
BM 
 
Treosulfan 42 gr/m2 
Cyclophosphamide 120 mg/kg 
 
Acute 
skin 
Grade I 
 
CD3 = 100% donor 
CD15 = 100% donor 
P3 
p.Glu71Lys 
p.Glu96* 
 
 
Low IgG levels 
Low T/NK-Cells 
Reduced TRECs 
Abnormal mitogen 
stimulation 
 
Exomphalos 
Pyloric/Ileal atresias 
Microcolon 
Autoimmune 
enterocolitis (PE) 
 
Steroids 
 
Unrelated 
HLA 12/12 
 
PBSC 
 
Treosulfan 36 gr/m2 
Fludarabine 150 mg/m2 
Alemtuzumab 1 mg/kg 
 
None 
 
CD3 = 96% donor 
CD15 = 7% donor 
P4 
p.K606R 
p.S672P 
Low IgG levels 
Low T cells 
Absent TRECs 
Abnormal mitogen 
stimulation 
Pyloric stenosis 
Jejunal and colonic 
atresias 
Microcolon 
None Sibling 
HLA 9/10  
BM Equine ATG 30 mg/kg None CD3 = 100% donor 
CD15 = 6% donor 
 
Table 1. Characteristics of patients with TTC7A deficiency undergoing HSCT (TRECs = T-Cell Receptor Excision Circles, PE = panenteric (small and 
large bowel), D/AC/TC = Duodenum/Ascending Colon/Transverse Colon, IS = Immunesupression, CB = cord blood, BM = bone marrow, PBSC = 
peripheral blood stem cells, TBI = total body irradiation , ATG = anti-thymocyte globulin). Additional data on histological evolution post HSCT in 
supplemental material.  
Figure 1. Pedigree for patient 2 with TTC7A deficiency (A). Integrative Genomics Viewer  of whole exome sequencing data from patient 2 (B): 
Broad grey bars represent sequenced reads aligned to the reference genome. Thin grey bars represent missing/deleted segments (large 34 base pair 
deletion demonstrated in exon one, confirmed on Sanger sequencing). H&E stained gut biopsies taken pre HSCT and 6 months and 18 months post 
HSCT (C, from left to right) from patient 2. Unfilled white arrows: apoptotic debris. Filled white arrows: inilftration of the lamina propria with lymphocytes, 
eosinophils, plasma cells and neutrophils. Position of all causative mutations within TTC7A gene (D, top line: Exon 1-20) and position within TTC7A 
protein (lower line: Tetratricopeptide repeat (TPR) domains 1-9) for all four patients.   
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